SATIVEX / NABIXIMOLS – a cannabis extract spray


Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis                                                             (full – 2005)


Sativex Drug Momograph                     (monograph – 2005)


Sativex: Fact Sheet                     (full – 2005)


Sativex: Health Care Professional letter                    (letter – 2005)


Sativex produced significant improvements in a subjective measure of spasticity (abst – 2005)


Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance.      (abst – 2005)


Conditional okay for cannabis prescription drug                       (news – 2005)


Cannabis-Based Drug Relieves Arthritis Pain                 (news – 2005)


Cannabis-based medicine relieves the pain of rheumatoid arthritis and suppresses the disease       (news – 2005)                


Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis                                                       (full – 2006)  AT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=2240&resourcetype=HWCIT


Cannabinoids In Medicine: A Review Of Their Therapeutic Potential                  (full – 2006)


The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis   (letter – 2006)


Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.                                                                  (abst – 2006)


Randomised controlled study of cannabis-based medicine (Sativex®) in patients suffering from multiple sclerosis associated detrusor overactivity                                                                    (abst – 2006)


Sativex® in patients with symptoms of spasticity due to multiple sclerosis (abst – 2006)


Combined cannabinoid therapy via an oromucosal spray              (abst – 2006)



Sativex showed positive effects in 65 per cent of patients with chronic diseases (news – 2006)


Sativex: Fact Sheet               (full – 2007)


Sativex: Health Care Professional letter                   (letter – 2007)


Cannabis; adverse effects from an oromucosal spray.                (abst – 2007)


Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis- based medicine. (abst – 2007)                    


Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. (abst – 2007)                           


Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial                                                    (abst – 2007)


Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.

(abst – 2007)     


Cannabinoids Associated With “More Restful Sleep,” Study Says             (news – 2007)


Cannabinoids in the management of difficult to treat pain              (full – 2008)


Emerging strategies for exploiting cannabinoid receptor agonists as medicines. (full – 2009)


Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. (full – 2009)                              


Summary of Product Characteristics- Sativex Oralmucosal Spray             (full – 2010)


Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis                                                      (abst – 2010)       AT=&fullte  xt=cannabis&searchid=1&FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT


Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. (abst – 2010)                         


Emerging treatment options for spasticity in multiple sclerosis; clinical utility of cannabinoids      (link to PDF – 2011) ll&recNo=30&uiLanguage=en


Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.                                                             (abst – 2011)


Subjective and physiological effects after controlled Sativex and oral THC administration.          (abst – 2011)                             


A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.  (abst – 2011)


A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.     (abst – 2011)


THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.                                                   (abst – 2011)




Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease.                                                 (abst – 2011) 


Plasma cannabinoid pharmacokinetics following controlled oral delta9- tetrahydrocannabinol and oromucosal cannabis extract administration                                                                               (abst – 2011) kinetics_following_controlled_oral_delta9_tetrahydrocannabinol_and_oromucosal_cannabis_extract_admi  nistration_


Is Pot Good For You?                 (news – 2011),9171,1003570,00.html


Towards the use of non-psychoactive cannabinoids for prostate cancer.             (full – 2012)


Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report. (full – 2012)                          


Cannabinoids: Novel Medicines for the Treatment of Huntington’s Disease. (abst – 2012)                           


Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial.                                                     (abst – 2012)


A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.   (abst – 2012)                              


Subjective and Physiological Effects of Oromucosal Sprays Containing Cannabinoids (Nabiximols): Potentials and Limitations for Psychosis Research.                                                                (abst – 2012)


Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System. (abst – 2012)                             


Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.                                                            (abst – 2012)


Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? (abst – 2012)                           


Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.    (abst – 2012)







Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.     (abst – 2012)                  


Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. (abst – 2012)                          


Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids  (abst – 2012)                             


Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis.                                               (abst – 2012)


Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?                                                                (abst – 2012)


Treatment of Tourette syndrome with cannabinoids.               (abst – 2012)


A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.                                                                                                (abst – 2012)


Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids  (abst – 2012)                         


What place for cannabis extract in MS?            (abst – 2012)


Neuromodulators for pain management in rheumatoid arthritis               (abst – 2012)


Cannabinoid formulation benefits opioid-refractory pain                       (news – 2012)


Cannabinoid Shown Effective as Adjuvant Analgesic for Cancer Pain                   (news – 2012)


Pot-based prescription drug looks for FDA OK                   (news – 2012)


Cannabinoid therapy helps provide effective analgesia for cancer patients with pain (news – 2012)  cancer-patients-with-pain.aspx


Towards the use of non-psychoactive cannabinoids for prostate cancer                     (full – 2013)


Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.          (abst – 2013)                      


The pharmacologic and clinical effects of medical cannabis.                       (abst – 2013)


A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.                                                                (abst – 2013)


Multiple sclerosis and the blood-central nervous system barrier.                      (abst – 2013)

Share a link for